The study demonstrated a paradigm shift in treating AML, proving that genetic information matching leads to better survival rates than traditional one-size-fits-all treatment. Patients who opted for precision medicine experienced lower early death rates and superior overall survival compared to those receiving standard of care.
Boehringer Ingelheim announces new data on flibanserin in pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD), showing significant improvements in sexual desire and overall functioning. The study found that 48.3% of women receiving flibanserin reported feeling very much improved, compared to 30.3% on placebo.
A new study found that women with low sexual desire experience personal and emotional distress, including negative emotions like dissatisfaction and guilt. The study identified 5,098 women with low sexual desire, who reported significant correlations between their level of desire and associated distress.
Flibanserin demonstrates significant improvements in sexual functioning, desire, and distress related to low sexual desire in pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). The treatment increased satisfying sexual events and sexual desire, while decreasing distress associated with HSDD.
Patients with relapsing forms of MS taking Betaseron experienced a sustained 40% reduction in annual relapse rates over 16 years. Long-term treatment showed slower disease progression, with those on therapy reaching EDSS 6.0 after a median time of 13 years.
The updated data show that 51% of patients originally assigned to the Betaseron 250 mcg group can walk with or without assistance, compared to 45% in the placebo group. Additionally, 95% of patients in the Betaseron 250 mcg group are still alive after 16 years, compared to 83% in the placebo group.
Researchers found that asthma patients frequently move between severity categories, with no single parameter reliably predicting overall severity. This variability may lead to underestimation or overestimation of asthma severity, emphasizing the importance of proper management and daily maintenance treatments.
A study found that Advair Diskus can reduce inhaled corticosteroid doses by 60% without compromising asthma control. The treatment, which combines an inhaled long-acting bronchodilator and corticosteroid, was shown to improve pulmonary function, symptom-free days, and albuterol use in patients requiring higher doses of corticosteroids.
Exposure to inhaled corticosteroids was associated with a decreased risk of death and longer survival in patients with chronic obstructive pulmonary disease (COPD). ICS plus salmeterol combination showed significant reduction in mortality risk.
A recent survey of 968 women aged 15-59 found that nearly 60% were told their pain is normal by their Ob/Gyn or a friend/family member. Chronic pelvic pain affects many lives, but often takes years to receive an accurate diagnosis.
Undertreated asthma has a significant impact on women's lives, affecting their physical activities, relationships, and overall well-being. Many women report poorly controlled symptoms, anxiety, and worry about their condition.